Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK ‐rearranged lung cancer

Lorlatinib, a third‐generation anaplastic lymphoma kinase (ALK)‐tyrosine kinase inhibitor (TKI) with a broad coverage against ALK mutations, has demonstrated dramatic effects in patients with ALK‐rearranged lung cancer. The mechanisms of acquired resistance to lorlatinib by secondary ALK compound mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Taniguchi, Hirokazu, Akagi, Kazumasa, Dotsu, Yosuke, Yamada, Tadaaki, Ono, Sawana, Imamura, Erika, Gyotoku, Hiroshi, Takemoto, Shinnosuke, Yamaguchi, Hiroyuki, Sen, Triparna, Yano, Seiji, Mukae, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807501/
https://www.ncbi.nlm.nih.gov/pubmed/36086904
http://dx.doi.org/10.1111/cas.15579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807501/
https://www.ncbi.nlm.nih.gov/pubmed/36086904
http://dx.doi.org/10.1111/cas.15579

Ejemplares similares